<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03177824</url>
  </required_header>
  <id_info>
    <org_study_id>123sc</org_study_id>
    <nct_id>NCT03177824</nct_id>
  </id_info>
  <brief_title>Sildenafil Citrate for Treatment of Growth-restricted Fetuses</brief_title>
  <official_title>Sildenafil Citrate for Treatment of Growth-restricted Fetuses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of Sildenafil citrate therapy on neonatal
      outcomes in women with fetal growth restriction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>date of delivery after Sildenafil citrate administration.</measure>
    <time_frame>for 6 months from the beginning of the study</time_frame>
    <description>the study aims to assess date of delivery of growth restricted fetus after administration of sildenafil citrate by dose of 20mg three times per day , and that will be done by following up women with growth redistricted fetuses in Ain shams university maternity hospital till time of delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expected fetal weight by serial ultrasound after Sildenafil citrate administration</measure>
    <time_frame>every two weeks after drug intake for 6 months from the beginning of the study</time_frame>
    <description>the Expected fetal weight in grams by serial ultrasound is assessed in women with growth redistricted fetuses in Ain shams university maternity hospital after Sildenafil citrate administration and till time of delivery .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color Doppler changes on umbilical artery</measure>
    <time_frame>weekly after drug intake for 6 months from the beginning of the study</time_frame>
    <description>Color Doppler changes on umbilical artery is assessed in women with growth restricted fetuses in Ain shams university maternity hospital after Sildenafil citrate administration and till time of delivery .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal outcomes as regard birth weight</measure>
    <time_frame>for 6 months from the beginning of the study</time_frame>
    <description>the study aims to assess neonatal outcomes as regard, birth weight in growth restricted fetus after administration of sildenafil citrate and that will be done by following up women with growth redistricted fetuses in Ain shams university maternity hospital till time of delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal outcomes as regard APGAR score</measure>
    <time_frame>for 6 months from the beginning of the study</time_frame>
    <description>the study aims to assess neonatal outcomes as regard APGAR score in growth restricted fetus after administration of sildenafil citrate and that will be done by following up women with growth redistricted fetuses in Ain shams university maternity hospital till time of delivery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fetal Growth Restriction</condition>
  <arm_group>
    <arm_group_label>S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil citrate (25mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oral tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil Citrate 25Mg Tab</intervention_name>
    <description>Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.</description>
    <arm_group_label>S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score</description>
    <arm_group_label>P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maternal age ranging from 20-40 years.

          -  Gestational age 28-37 weeks.

        Exclusion Criteria:

          -  Obese patients (BMI &gt;30 kg/m2).

          -  Patients with medical disorders: cardiac diseases, pulmonary diseases, liver disease,
             renal disease, previous history of seizures, hearing loss.

          -  Drug interactions, such as users of any vasodilator agents, omeprazole, clarithromycin
             and amoxicillin.

          -  Fetal distress.

          -  Pregnancy of multiple fetuses.

          -  Congenital fetal malformation or chromosomal abnormalities.

          -  Diastolic blood pressure more than 110 mmHg.

          -  Hypersensitivity to the drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shaimaa mohamed Ezz el Din, MB ChB</last_name>
    <phone>+201000484298</phone>
    <email>dr.shaimaaezz666@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams matrnity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shaimaa mohamed Ezz el Din, MB ChB</last_name>
      <phone>+201000484298</phone>
      <email>dr.shaimaaezz666@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Shaimaa Mohamed Ezz el din</investigator_full_name>
    <investigator_title>resident of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

